LB Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by LB Pharmaceuticals Inc. on June 3, 2026. The filing was submitted on June 9, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol LBRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Two proposals were submitted to a vote of security holders:
- Proposal 1 – Election of Directors: Stockholders elected three Class I directors to serve three-year terms until the 2029 Annual Meeting.
- Robert A. Lenz, M.D., Ph.D.: 20,059,577 votes For; 8,004 Withheld; 3,216,636 Broker Non-Votes.
- Rebecca Luse: 18,530,680 votes For; 1,536,901 Withheld; 3,216,636 Broker Non-Votes.
- Ran Nussbaum: 18,748,511 votes For; 1,319,070 Withheld; 3,216,636 Broker Non-Votes.
- Proposal 2 – Ratification of Auditors: Stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Voting Results: 23,275,974 For; 5,490 Against; 2,753 Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the final voting tallies for the Annual Meeting.
Key Facts for Investor Verification
- Confirm the terms of office for the newly elected directors (Class I, three-year term).
- Verify the appointment of BDO USA, P.C. as the auditor for the fiscal year ending December 31, 2026.
- Note the significant number of Broker Non-Votes (3,216,636) recorded for the director elections.
- Review the definitive proxy statement filed on April 23, 2026, for detailed background on the proposals.